Drug Trial Radar · NCT07751042
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Jun 30, 2026
Primary completion
Jul 17, 2030
Study completion Nov 15, 2030
Sponsor
- Lead sponsor
- Strand Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Protocol Title: Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-003 Delivered by Intravenous Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab. Protocol Name: ASCENT-1: Activated, Selective, Controlled Expression of a Novel Programmable mRNA Therapeutic
Conditions
- Advanced Solid Tumor
Interventions
STX-003Biological
STX-003 is a LNP formulated self-replicating mRNA encoding the therapeutic payload human IL-12 (hIL-12) with miRNA target sites to sense specific endogenous miRs.
KEYTRUDA®Biological
Pembrolizumab (Keytruda USPI 2026) is a marketed PD-1 blocking humanized monoclonal IgG4 kappa antibody.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of TEAEs, SAEs, and DLTsTime frame: From time of informed consent until 30 days after the last dose of investigational product.
- Occurrence of changes from baseline in patients' clinical safety laboratory values and vital signs to assess the safety and tolerability of STX-003.Time frame: From Day 1 until 30 days after last dose of STX-003
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
HonorHealth Research Institute
Scottsdale, Arizona · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
Melanoma Institute Australia
Wollstonecraft, New South Wales, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.